Transmission blocking vaccine studies in leishmaniasis: II. Effect of immunisation using Leishmania major derived 63 kilodalton glycoprotein, lipophosphoglycan and whole parasite antigens on the course of L. Major infection in BALB/c mice

East African Medical Journal

Volumn 78, Issue 2, 2001, Pages 90-92

  Tonui, W K ^a   Mbati, P A ^a   Anjili, C O ^a   Orago, A S ^b   Turco, S J ^c   Githure, J I ^a   Koech, D K ^a  

^a KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^b KENYATTA UNIVERSITY   (Kenya)

^c UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP63, LEISHMANIA; GLYCOSPHINGOLIPID; LIPOPHOSPHOGLYCAN; METALLOPROTEINASE; PARASITE ANTIGEN; PROTOZOAL VACCINE;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BLOOD; DISEASE CARRIER; DISEASE COURSE; DISEASE MODEL; DISEASE TRANSMISSION; DRUG SCREENING; IMMUNOLOGY; LEISHMANIA MAJOR; MOUSE; PARASITOLOGY; PHLEBOTOMUS; SKIN LEISHMANIASIS; TIME;

ANIMALS; ANTIGENS, PROTOZOAN; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DRUG EVALUATION, PRECLINICAL; GLYCOSPHINGOLIPIDS; INSECT VECTORS; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; METALLOENDOPEPTIDASES; MICE; MICE, INBRED BALB C; PHLEBOTOMUS; PROTOZOAN VACCINES; TIME FACTORS;

EID: 0035542293     PISSN: 0012835X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Desjeux, P. Cutaneous leishmaniasis: clinical aspects. In Dowlati, Y., Modabber, F., editors, Clinics in dermatology, vol. 14. Amsterdam: Elsevier Science B.V., p. 417-423, 1996.
2. Howard, J.G., Liew, F.Y., Hale, C. and Nicklin, S. Prophylactic immunization against experimental leishmaniasis .II. Further characterization of protective immunity against fatal Leishmania tropica infection. J. Immun. 1982; 132: 450-455.
3. Kaul, S.M., Wattal, B.L., Bhatnagar, U.N. and Mathur, K.K. Preliminary observations on the susceptibility status of Phlebotomus argentipes and Phlebotomus papatasi to DDT in two districts of northern Bihar (India). J. Commun. Dis. 1978; 10: 208-211.
4. Abath, F.G., Montenegro, S.M. and Gomes, Y.M. Vaccines against human parasitic diseases: an overview. Acta tropica, 1998; 71:237-54.
5. Doherty, T.M. and Coffman, R.L. Leishmania major: Effect of infectious dose on T cell subset development in BALB/c mice. Exp. Parasit. 1996; 84:124-135.
6. Tonui W.K., Mbati P.A., Anjili, C.O., Orago, A.S., Turco, S.J., Githure, J.I. and Koech, D. K. Transmission blocking vaccine studies in leishmaniasis: I. Lipophosphoglycan (LPG) is a promising transmission blocking vaccine molecule against cutaneous leishmaniasis. East Afr. Med. J. 2000; 78:84-93.
7. Nolan, T.J. and Farrell, J.P. Experimental infections of the multimammate rat (Mastomys natalensis) with Leishmania donovani and Leishmania major. Amer. J. trop. Med. Hyg. 1987; 36:264-266.
8. Scott, P.A. and Farrell, J.P. Experimental cutaneous leishmaniasis: disseminated leishmaniasis in genetically susceptible and resistant mice. Amer. J. trop. Med. Hyg. 1982; 32: 230-238.
9. Modabber, F. Experiences with vaccines against cutaneous leishmaniasis: of men and mice. Parasitology, 1989; 98: S49-S60.
10. Scott, P.A., Pearce, E., Natvitz, P. and Sher, A. Vaccination against cutaneous leishmaniasis in a marine model I. Induction of Protective Immunity With a Soluble Extract of Promastigotes. J. Immunol. 1987; 139:221-227.
11. Convit, J., Rondon, A., Ulrich, M., Bloom, B., Castellanos, P.L., Pinardi, M.E., Castes, M and Garcia, L. Immunotherapy versus chemotherapy in localized cutaneous leishmaniasis. Lancet, 1987; 1: 401-404.